September 22, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Re: *Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*

Dear Sir,

Subject: **Update on the Company's Baddi (India) Facility**

Further to our intimation dated June 22, 2022, regarding outcome of the US FDA inspection, the "Official Action Indicated" (OAI) status for Baddi continues. Following the inspection in June 2022, the US FDA had issued a Form-483 with six observations to the Baddi facility.

The Company does not believe that this will have any material impact on the US business at this stage. The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.

This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2022.09.22 21:28:35 +05'30'

Harish Kuber
Company Secretary & Compliance Officer